AAA
SYRE icon

Affinity Asset Advisors’s Spyre Therapeutics SYRE Stock Holding History

Affinity Asset Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114M Hold
1,279,134
– – 5.13% 3
2026
Q1 		$64.5M Sell
1,279,134
-153,457
-11% -$5.79M 3.33% 7
2025
Q4 		$46.9M Buy
1,432,591
+13,292
+0.9% +$347K 2.67% 10
2025
Q3 		$23.8M Buy
1,419,299
+812,621
+134% +$13.3M 2.07% 18
2025
Q2 		$9.08M Buy
606,678
+125,000
+26% +$1.85M 1.24% 27
2025
Q1 		$7.77M Sell
481,678
-342,650
-42% -$7.13M 0.74% 32
2024
Q4 		$19.2M Buy
824,328
+325,908
+65% +$9.56M 2.57% 11
2024
Q3 		$14.7M Sell
498,420
-15,000
-3% -$418K 2% 17
2024
Q2 		$12.1M Buy
513,420
+103,420
+25% +$3.49M 1.39% 21
2024
Q1 		$15.6M Sell
410,000
-107,554
-21% -$3.12M 1.93% 16
2023
Q4 		$11.1M Buy
517,554
+275,257
+114% +$3.79M 2.03% 19
2023
Q3 		$2.97M Buy
242,297
+46,297
+24% +$612K 0.83% 36
2023
Q2 		$2.21M Buy
+196,000
New +$929K 0.77% 37

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Affinity Asset Advisors's SYRE Position: Q2 2026 in Review

Affinity Asset Advisors held its Spyre Therapeutics (SYRE) position steady in Q2 2026 at 1,279,134 shares worth $114M. The position accounts for 5.13% of the portfolio, ranked #3.

Affinity Asset Advisors first reported a position in SYRE in Q2 2023 and has held it in 13 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Affinity Asset Advisors held 1,279,134 shares of Spyre Therapeutics worth $114M as of Q2 2026.
  • Affinity Asset Advisors left its Spyre Therapeutics share count unchanged in Q2 2026.
  • Spyre Therapeutics made up 5.13% of Affinity Asset Advisors's portfolio in Q2 2026, its #3 holding.
  • Affinity Asset Advisors first reported a position in Spyre Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.